skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index
Show only
Refined by: New Records: New From Last Week remove New Records: New From Last 3 Month remove subject: Cancer remove
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Clinical Trial: Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial
Material Type:
Newsletter Article
Add to My Research

Clinical Trial: Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial

US Fed News Service, Including US State News, 2024

Copyright HT Digital Streams Limited Jun 3, 2024

Digital Resources/Online E-Resources

2
Live from ASCO 2024 | Updated Data of Bcl-2 Inhibitor Lisaftoclax Combined with Azacitidine in Patients with AML Demonstrate Promising Efficacy and Manageable Safety
Material Type:
Newsletter Article
Add to My Research

Live from ASCO 2024 | Updated Data of Bcl-2 Inhibitor Lisaftoclax Combined with Azacitidine in Patients with AML Demonstrate Promising Efficacy and Manageable Safety

PR Newswire, 2024

Copyright PR Newswire Association LLC Jun 4, 2024

Digital Resources/Online E-Resources

3
Press Release: Encouraging New Data Presented on Kite's Yescarta(R) for Relapsed/Refractory Central Nervous System Lymphoma
Material Type:
Newsletter Article
Add to My Research

Press Release: Encouraging New Data Presented on Kite's Yescarta(R) for Relapsed/Refractory Central Nervous System Lymphoma

Dow Jones Institutional News, 2024

Copyright Dow Jones & Company Inc. Jun 3, 2024

Digital Resources/Online E-Resources

4
Press Release: Live from ASCO 2024 | Updated Data of Bcl-2 Inhibitor Lisaftoclax Combined with Azacitidine in Patients with AML Demonstrate Promising Efficacy and Manageable Safety
Material Type:
Newsletter Article
Add to My Research

Press Release: Live from ASCO 2024 | Updated Data of Bcl-2 Inhibitor Lisaftoclax Combined with Azacitidine in Patients with AML Demonstrate Promising Efficacy and Manageable Safety

Dow Jones Institutional News, 2024

Copyright Dow Jones & Company Inc. Jun 4, 2024

Digital Resources/Online E-Resources

5
UAMS Researchers Find That Better Access to Physical Activity Could Provide Boost for Rural Cancer Survivors
Material Type:
Newsletter Article
Add to My Research

UAMS Researchers Find That Better Access to Physical Activity Could Provide Boost for Rural Cancer Survivors

Targeted News Service, 2024

Targeted News Service

Digital Resources/Online E-Resources

6
Unmet need for cancer palliative care in India
Material Type:
Article
Add to My Research

Unmet need for cancer palliative care in India

BMJ supportive & palliative care, 2024-06, p.spcare-2024-004978 [Peer Reviewed Journal]

Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ. ;2024 Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 2045-435X ;EISSN: 2045-4368 ;DOI: 10.1136/spcare-2024-004978 ;PMID: 38834235

Digital Resources/Online E-Resources

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Show only

  1. Peer-reviewed Journals (1)

Searching Remote Databases, Please Wait